We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Gene Panel Differentiates Survival Outcomes in Humans Infected with Ebola

By LabMedica International staff writers
Posted on 31 Jan 2017
A team of molecular virologists used transcriptome data from individuals infected with Ebola virus and from convalescent patients recovering from the disease to identify early stage host factors that were associated with the acute illness and those that differentiated patients who survived from those that died.

The transcriptome is the set of all messenger RNA molecules in one cell or a population of cells. More...
It differs from the exome in that it includes only those RNA molecules found in a specified cell population, and usually includes the amount or concentration of each RNA molecule in addition to the molecular identities.

Investigators at the University of Liverpool used genomic techniques to identify and quantify messenger RNA (mRNA) expression in the blood of Ebola patients in Guinea who either went on to survive or die from the acute infection. These results were compared to blood samples from a separate group of survivors who had recovered from infection and were now free of the Ebola virus.

Results revealed that individuals who succumbed to the disease showed stronger upregulation of interferon signaling and acute phase responses compared to survivors during the acute phase of infection. Particularly notable was the strong upregulation of albumin and fibrinogen genes, which suggested significant liver pathology. Cell subtype prediction using messenger RNA expression patterns indicated that NK-cell populations increased in patients who survived infection.

Differences in immune cell populations predicted through analysis of gene expression patterns were validated on an independent group of Ebola virus patients using flow cytometry to directly measure the same cell types in patient blood. Machine learning was used to identify a panel of genes whose abundance could be used to predict the outcome of infection at the acute phase. This panel was validated on a separate independent group of patients with fatal or non-fatal outcome and whose viral loads were similar and was found to accurately predict outcome.

Senior author Dr. Julian Hiscox, professor of virology at the University of Liverpool, said, "Our study provides a benchmark of Ebola virus infection in humans and suggests that rapid analysis of a patient's response to infection in an outbreak could provide valuable predictive information on disease outcome."

The study was published in the January 19, 2017, online edition of the journal Genome Biology.


Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
hCG Whole Blood Pregnancy Test
VEDALAB hCG-CHECK-1
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.